Surabaya

Researchers are investigating the cardiovascular disease CVD risk profile among adults newly diagnosed with type 2 diabetes mellitus T2DM in Southeast Asia. This observational study uses retrospective chart reviews from five Southeast Asian countries to understand how CVD risk is distributed in these patients, based on data from the year before diagnosis and about the first year after diagnosis. The study focuses on adults aged 40 to 69 years who have recently started anti-hyperglycemic treatment. Participants are identified based on their diagnosis of T2DM between January 2022 and December 2023. The study does not involve any treatment administration as it is observational, relying on existing health records. Researchers collect data on cardiometabolic profiles at baseline, including measurements such as blood pressure, waist and hip circumference, height, weight, cholesterol levels, blood sugar levels, kidney function markers, and classification into CVD risk categories. During the study, participants medical records are reviewed to gather baseline measurements at the index date or within the previous 12 months if unavailable on the index date. The main outcomes measured include systolic blood pressure, lipid profiles, glycated hemoglobin, fasting glucose, kidney function tests, and CVD risk categorization. The study tracks participants health status for up to one year following their diagnosis to analyze cardiovascular risk factors and outcomes.

This trial is for adults who have had an acute ischemic stroke caused by a blood clot blocking a brain vessel. It focuses on people whose stroke occurred or was discovered more than 4.5 hours ago, including those who woke up with stroke symptoms. The study aims to find out if the medicine tenecteplase helps recovery when given after this 4.5-hour window, compared to standard medical care. Tenecteplase is already used within 4.5 hours after stroke onset, but this study tests its effect when given later. Participants are randomly assigned to one of two groups one receives a single injection of tenecteplase into a vein, and the other receives the usual standard treatment. Both groups have an equal chance of receiving either treatment. The study lasts about three months, starting with approximately one week of hospital stay. During the study, participants have seven clinical examinations or visits, with the final two visits conducted remotely from home to allow for easier participation. Throughout the study, doctors regularly assess participants recovery using a scale that measures disability and dependence in daily activities. They also monitor overall health and record any side effects. The main outcome measured is the level of recovery 90 days after treatment, comparing the two groups. This includes neurological improvement, bleeding events, and survival over the study period.

Researchers are evaluating the real-world effectiveness and safety of Nebilet4 nebivolol in adults with hypertension across seven Asian countries. This multinational, multicenter, observational, and prospective study aims to assess blood pressure changes, treatment adherence, quality of life, prescription patterns, and cardiovascular outcomes over up to three years. The study also compares Nebilet4 used alone versus in combination therapy and investigates the relationship between home and office blood pressure measurements. Participants include about 5,000 adults newly diagnosed with or having uncontrolled hypertension who have recently started Nebilet4 or been on it no more than two weeks. Patients are followed regularly for 12, 24, and 36 months, with blood pressure measured at each visit and home readings encouraged. The study collects data on medication dosing and frequency, adherence, and cardiovascular risk factors, while monitoring major adverse cardiac events such as heart attack, stroke, and cardiovascular death. During the study, participants complete questionnaires to assess quality of life and medication adherence every few months. Data are recorded through an electronic system ensuring consistency across sites. Researchers evaluate changes in systolic and diastolic blood pressure and the proportion achieving target blood pressure goals. Safety and any adverse events are documented, with follow-up visits extending up to three years to provide insights into the long-term management of hypertension with Nebilet4.